Literature DB >> 11878696

The new neuromuscular blocking agents: do they offer any advantages?

E W Moore1, J M Hunter.   

Abstract

The pharmacodynamics and pharmacokinetics of the two most recent aminosteroid neuromuscular blocking drugs to become available, rapacuronium bromide (Org 9487) and rocuronium bromide are reviewed. Two new classes of drug with neuromuscular blocking properties, the bis-tetrahydroisoquinolinium chlorofumarates and the tropinyl diester derivatives are introduced. Comparisons between these drugs and mivacurium and cisatracurium are made. Rapacuronium 1.5 mg kg(-1) (ED95 1 mg kg(-1)), produces maximal neuromuscular block in 54 s. Time to recovery of the train-of-four ratio to 0.7 is achieved within 20 min after neostigmiine 0.05 mg kg(-1) given at 2 min. The plasma clearance of rapacuronium is 7-8 ml kg(-1) min(-1). Rapacuronium undergoes hepatic metabolism: no prolongation of effect has been reported after a single bolus or a short infusion in patients with hepatic or renal failure. Org 9488 is the 3-desacetyl metabolite of rapacuronium, which has neuromuscular blocking properties. Its much lower clearance (1.28 ml kg(-1) min(-1)) and plasma equilibration constant (0.105 min(-1)) may limit the prolonged use of rapacuronium. Rocuronium given at 2xED95 produces maximal neuromuscular block in 1 min. Spontaneous recovery of the train-of-four ratio to 0.7 takes over 40 min. Rocuronium has a plasma clearance of 4 ml kg(-1) min(-1). Its pharmacodynamics are altered in hepatic and renal disease. A number of anaphylactoid reactions to rocuronium have been reported recently. The bis-tetrahydroisoquinolinium chlorofumarate GW280430A has an ED95 of 0.19 mg kg(-1). Given at three times this dose, onset of neuromuscular block occurs within 100 s; the duration of block is 8-9 min. Following a 2 h infusion, the recovery index does not seem to be increased. Early studies suggest that this drug has no adverse cardiovascular or respiratory side-effects. The tropinyl diester derivative G-1-64 will produce 80-90% neuromuscular block in less than 2 min using 3xED80. Ninety per cent recovery of the first twitch of the train-of-four occurs after 5-7 min using one ED80. A recovery index of less than 2 min has been reported in rats. All the tropinyl diesters appear to produce vagal block.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11878696     DOI: 10.1093/bja/87.6.912

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  7 in total

1.  Efficacy and safety of sugammadex for neuromuscular blockade reversal in pediatric patients: an updated meta-analysis of randomized controlled trials with trial sequential analysis.

Authors:  Bingchen Lang; Lu Han; Linan Zeng; Qianqian Zhang; Shouming Chen; Liang Huang; Zhijun Jia; Qin Yu; Lingli Zhang
Journal:  BMC Pediatr       Date:  2022-05-19       Impact factor: 2.567

2.  Infusions of rocuronium and cisatracurium exert different effects on rat diaphragm function.

Authors:  Dries Testelmans; Karen Maes; Patrick Wouters; Scott K Powers; Marc Decramer; Ghislaine Gayan-Ramirez
Journal:  Intensive Care Med       Date:  2007-03-15       Impact factor: 17.440

3.  Rocuronium-induced neuromuscular block after long pretreatment of clonidine in rabbits.

Authors:  Min Seok Koo; Nam Yun Kim; Hee Jong Lee; Sung Wook Yoon; Kyo Sang Kim
Journal:  Korean J Anesthesiol       Date:  2010-09-20

4.  The Benefit of Neuromuscular Blockade in Patients with Postanoxic Myoclonus Otherwise Obscuring Continuous Electroencephalography (CEEG).

Authors:  Christopher R Newey; Alejandro Hornik; Meziane Guerch; Anantha Veripuram; Sushma Yerram; Agnieszka Ardelt
Journal:  Crit Care Res Pract       Date:  2017-02-06

Review 5.  Factors that affect the onset of action of non-depolarizing neuromuscular blocking agents.

Authors:  Yong Beom Kim; Tae-Yun Sung; Hong Seuk Yang
Journal:  Korean J Anesthesiol       Date:  2017-09-28

6.  Azemiopsin, a Selective Peptide Antagonist of Muscle Nicotinic Acetylcholine Receptor: Preclinical Evaluation as a Local Muscle Relaxant.

Authors:  Irina V Shelukhina; Maxim N Zhmak; Alexander V Lobanov; Igor A Ivanov; Alexandra I Garifulina; Irina N Kravchenko; Ekaterina A Rasskazova; Margarita A Salmova; Elena A Tukhovskaya; Vladimir A Rykov; Gulsara A Slashcheva; Natalya S Egorova; Inessa S Muzyka; Victor I Tsetlin; Yuri N Utkin
Journal:  Toxins (Basel)       Date:  2018-01-07       Impact factor: 4.546

7.  Neuromuscular Electrical Stimulation in Patients With Severe COVID-19 Associated With Sepsis and Septic Shock.

Authors:  Renato Fraga Righetti; Samantha Torres Grams; Wesla Neves da Silva Costa; Leandro Teixeira Saraiva; Isabel Chateaubriand Diniz de Salles; Wellington Pereira Yamaguti
Journal:  Front Med (Lausanne)       Date:  2022-02-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.